734 related articles for article (PubMed ID: 28262777)
21. Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates.
Swierzko AS; Atkinson AP; Cedzynski M; Macdonald SL; Szala A; Domzalska-Popadiuk I; Borkowska-Klos M; Jopek A; Szczapa J; Matsushita M; Szemraj J; Turner ML; Kilpatrick DC
Mol Immunol; 2009 Feb; 46(4):551-8. PubMed ID: 18950864
[TBL] [Abstract][Full Text] [Related]
22. [Influence of high glucose and mannose binding lectin complement pathway activation to IL-6 and TNF-alpha's expression by human renal glomerular endothelial cells].
Wu XH; Huang SM; Fan WX; Tang WX; Qiu HY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):90-4. PubMed ID: 21355310
[TBL] [Abstract][Full Text] [Related]
23. Current concepts in the management of diabetic nephropathy.
Waanders F; Visser FW; Gans RO
Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs for diabetic nephropathy.
Bruno S; Cattaneo D; Perico N; Remuzzi G
Expert Opin Emerg Drugs; 2005 Nov; 10(4):747-71. PubMed ID: 16262561
[TBL] [Abstract][Full Text] [Related]
25. A novel measurement method for activation of the lectin complement pathway via both mannose-binding lectin (MBL) and L-ficolin.
Inoshita H; Matsushita M; Koide S; Kusaba G; Ishii M; Onda K; Gi MJ; Nakata M; Ohsawa I; Horikoshi S; Ohi H; Tomino Y
J Immunol Methods; 2009 Sep; 349(1-2):9-17. PubMed ID: 19699205
[TBL] [Abstract][Full Text] [Related]
26. Renal C3 complement component: feed forward to diabetic kidney disease.
Kelly KJ; Liu Y; Zhang J; Dominguez JH
Am J Nephrol; 2015; 41(1):48-56. PubMed ID: 25662584
[TBL] [Abstract][Full Text] [Related]
27. Diabetic nephropathy - is this an immune disorder?
Tesch GH
Clin Sci (Lond); 2017 Aug; 131(16):2183-2199. PubMed ID: 28760771
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.
Arora MK; Singh UK
Vascul Pharmacol; 2013 Apr; 58(4):259-71. PubMed ID: 23313806
[TBL] [Abstract][Full Text] [Related]
29. Investigation of Complement-activating Pattern Recognition Molecules and Associated Enzymes as Possible Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis.
Petri C; Thiel S; Jensenius JC; Herlin T
J Rheumatol; 2015 Jul; 42(7):1252-8. PubMed ID: 26034144
[TBL] [Abstract][Full Text] [Related]
30. The pathogenesis of diabetic nephropathy: focus on microRNAs and proteomics.
Conserva F; Pontrelli P; Accetturo M; Gesualdo L
J Nephrol; 2013; 26(5):811-20. PubMed ID: 23543479
[TBL] [Abstract][Full Text] [Related]
31. Serum concentration of complement components of the lectin pathway in maintenance hemodialysis patients, and relatively higher levels of L-Ficolin and MASP-2 in Mannose-binding lectin deficiency.
Ishii M; Ohsawa I; Inoshita H; Kusaba G; Onda K; Wakabayashi M; Ohi H; Horikoshi S; Matsushita M; Tomino Y
Ther Apher Dial; 2011 Oct; 15(5):441-7. PubMed ID: 21974696
[TBL] [Abstract][Full Text] [Related]
32. Elevated levels of mannan-binding lectin in patients with type 1 diabetes.
Hansen TK; Thiel S; Knudsen ST; Gravholt CH; Christiansen JS; Mogensen CE; Poulsen PL
J Clin Endocrinol Metab; 2003 Oct; 88(10):4857-61. PubMed ID: 14557465
[TBL] [Abstract][Full Text] [Related]
33. Morbidity in relation to stage of diabetic nephropathy in type-2 diabetic patients.
Alebiosu CO; Odusan O; Jaiyesimi A
J Natl Med Assoc; 2003 Nov; 95(11):1042-7. PubMed ID: 14651370
[TBL] [Abstract][Full Text] [Related]
34. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.
Balakumar P; Arora MK; Ganti SS; Reddy J; Singh M
Pharmacol Res; 2009 Jul; 60(1):24-32. PubMed ID: 19427582
[TBL] [Abstract][Full Text] [Related]
36. JDRF perspective: bridging the gap-translational research to prevent progression of diabetic nephropathy.
Nickerson HD; Dutta S
Semin Nephrol; 2012 Sep; 32(5):512-6. PubMed ID: 23062993
[TBL] [Abstract][Full Text] [Related]
37. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy.
Navarro JF; Mora C
ScientificWorldJournal; 2006 Aug; 6():908-17. PubMed ID: 16906324
[TBL] [Abstract][Full Text] [Related]
38. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition.
Wang H; Vinnikov I; Shahzad K; Bock F; Ranjan S; Wolter J; Kashif M; Oh J; Bierhaus A; Nawroth P; Kirschfink M; Conway EM; Madhusudhan T; Isermann B
Thromb Haemost; 2012 Dec; 108(6):1141-53. PubMed ID: 23014597
[TBL] [Abstract][Full Text] [Related]
39. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
40. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44.
Degn SE; Jensen L; Olszowski T; Jensenius JC; Thiel S
J Immunol; 2013 Aug; 191(3):1334-45. PubMed ID: 23785123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
